Distribution of Phase I lung cancer trials may be consolidating at top-performing US sites
medicalxpress - Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly concentrated at the top 20 highest-volume clinical trial si…
AI Summary: A new analysis shows Phase I lung cancer trials are becoming concentrated at a relatively small number of leading U.S. centers, raising concerns about geographic inequity in access to early‑phase studies. The trend could speed drug development at elite sites while leaving patients in other regions with fewer experimental options and longer travel burdens.
- Conference highlights, care models and awareness (4)
- Consolidation at top U.S. Phase I centers (3)
- Early-phase trials and next-gen therapies (4)
- All Other Stories
Conference highlights, care models and awareness
Consolidation at top U.S. Phase I centers
Early-phase trials and next-gen therapies
All Other Stories
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial
Omar Nadeem / nature - Nature Medicine, Published online: 20 April 2026; doi:10.1038/s41591-026-04365-yAs presented at the 2026 AACR Annual Meeting, in a phase 2 trial, treatment of patients with high-risk smoldering multiple myeloma with BCMA-targeting CAR T cell therapy cilta…
AI Summary: The CAR-PRISM phase 2 study reports that ciltacabtagene autoleucel, a BCMA-directed CAR T therapy, produced meaningful responses in patients with high‑risk smoldering multiple myeloma, suggesting potential to delay progression to symptomatic disease and defer immediate treatment. Early results show promising efficacy with manageable toxicities, hinting at a shift toward treating disease earlier rather than later.
- CAR-PRISM results: compelling MRD negativity, potential treatment shift (4)
- Experts weigh in: praise, safety concerns, and clinical enthusiasm (4)
- Policy and IO context: regulation, immune engineering, industry implications (3)
- All Other Stories
CAR-PRISM results: compelling MRD negativity, potential treatment shift
Experts weigh in: praise, safety concerns, and clinical enthusiasm
Policy and IO context: regulation, immune engineering, industry implications
All Other Stories
Long-term Use of Immunotherapy May Be Safe for Patients With Alveolar Soft Part Sarcoma
Kathleen Medora / aacr - SAN DIEGO – Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma (ASPS), which primarily affects adolescents and young adults, who received immunotherapy beyond the standard two years, according to results from …
AI Summary: Observational data indicate extended checkpoint inhibitor therapy can be tolerated by patients with alveolar soft part sarcoma and may provide sustained disease control for many. The findings support considering prolonged treatment in select cases, while underscoring the need for vigilant monitoring for late toxicities and randomized trials to confirm benefit.
Zoldonrasib Shows Early Strength in Previously Treated KRAS G12D NSCLC
oncodaily - KRAS G12D has long been one of the most frustrating targets in thoracic oncology. It is biologically important, clearly druggable in theory, and yet patients with KRAS G12D-mutant non-small cell […]
AI Summary: Investigational KRAS(ON) inhibitor zoldonrasib produced effective, durable responses in patients with advanced KRAS G12D–mutated non‑small‑cell lung cancer after prior therapy. Early‑phase data show meaningful tumour shrinkage and a manageable safety profile, offering a targeted option for a mutation long considered untargetable and breathing new life into KRAS drug development.
- Experts on site: RAS inhibitors reshape NSCLC treatment landscape (5)
- Industry moves: BridgeBio reshuffles as KRAS race heats up (1)
- On the AACR floor: zoldonrasib delivers durable G12D responses (4)
- Perioperative and biomarker research reshapes precision care in NSCLC (4)
- All Other Stories
Experts on site: RAS inhibitors reshape NSCLC treatment landscape
Industry moves: BridgeBio reshuffles as KRAS race heats up
On the AACR floor: zoldonrasib delivers durable G12D responses
Perioperative and biomarker research reshapes precision care in NSCLC
All Other Stories
First-Line Zongertinib in Advanced HER2-Mutant NSCLC: A New Targeted Standard Begins to Take Shape
oncodaily - For years, HER2-mutant non-small-cell lung cancer sat in an uncomfortable place in thoracic oncology. It was clearly an oncogene-driven disease, but unlike EGFR-mutant or ALK-rearranged NSCLC, it did not have […]
AI Summary: Clinical trial data show zongertinib delivers strong antitumor activity as a first‑line treatment for patients with advanced HER2‑mutant non‑small cell lung cancer, positioning the drug as a potential new targeted standard. Robust response rates in previously untreated patients are prompting clinicians to rethink initial treatment choices while attention turns to long‑term safety and access.
Eating more fruits and vegetables tied to unexpected lung cancer risk
sciencedaily - A surprising new study suggests that eating a very healthy diet—packed with fruits, vegetables, and whole grains—might be linked to a higher risk of lung cancer in younger non-smokers. Researchers found that patients under 50 diagnosed with lung cancer of…
AI Summary: A new analysis links higher fruit-and-vegetable consumption to an unexpected rise in lung cancer risk among younger non‑smokers, with investigators pointing to pesticide residues on produce as a likely culprit. Researchers urge careful interpretation—don’t ditch your salad—while calling for stricter residue limits, better monitoring, and further study to untangle diet, toxins, and cancer risk.
Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors
Frank Vinluan / medcitynews - Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better efficacy, CrossBio’s dual approach could also fight drug resistance. The post El…
AI Summary: Eli Lilly agreed to acquire CrossBridge Bio for up to $300 million, adding small‑molecule oncology assets to its pipeline. The deal accelerates Lilly’s tumor‑targeting strategy, reflects Big Pharma’s preference for buying nimble biotech innovation, and highlights ongoing consolidation trends that determine where promising oncology programs ultimately end up.
ESMO 2026 Guideline: Redefining the Management of Metastatic Colorectal Cancer
oncodaily - Metastatic colorectal cancer (mCRC) represents a complex and biologically diverse disease in which treatment decisions increasingly depend on molecular characteristics, disease burden, and patient-specific factors. While therapeutic options have expanded …
AI Summary: The European Society for Medical Oncology released updated clinical practice guidelines for metastatic colorectal cancer, redefining diagnostic pathways, systemic therapy sequencing, and follow‑up standards. The guidance incorporates recent targeted and immunotherapy evidence to recommend practical treatment algorithms, prompting oncology centers to update protocols and payers to reassess coverage as clinicians translate recommendations into routine care.
AACR Announces 2026 Distinguished Service Award Recipients
oncodaily - The American Association for Cancer Research (AACR) has announced the recipients of its 2026 Distinguished Service Awards, recognizing individuals whose work has shaped the direction of cancer research, policy, and […]
AI Summary: The American Association for Cancer Research announced its 2026 Distinguished Service Award recipients, honoring leaders for exceptional contributions to cancer research, advocacy, and public engagement. The prizes celebrate scientific leadership across academia, clinical practice, and patient advocacy, reinforcing AACR’s priorities while handing the field a roster of role models to admire—and occasionally envy.
- Awards & grants: Distinguished Service, Trailblazers, scholar honors (4)
- Clinical highlights: Trials, company data, and therapeutic developments (5)
- On-site coverage: Live updates, press conferences, and recaps (4)
- Other: Attendee reflections and unrelated items (5)
- All Other Stories
Awards & grants: Distinguished Service, Trailblazers, scholar honors
Clinical highlights: Trials, company data, and therapeutic developments
On-site coverage: Live updates, press conferences, and recaps
Other: Attendee reflections and unrelated items
All Other Stories
New drug doubles 1-year survival in pancreatic cancer trial
medicalxpress - Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a year after diagnosis. But a new drug developed at Northwestern University may soon help patients live longer.
AI Summary: A Phase 3 study showed a novel agent markedly lengthened survival for people with metastatic pancreatic cancer, roughly doubling one-year survival versus standard care. The results, from the RASolute 302 program evaluating daraxonrasib/Revolution Medicines’ approach, represent an uncommon advance in a stubbornly lethal disease and could change treatment standards pending regulatory review.
- Clinicians celebrate landmark KRAS win; cautious optimism prevails (7)
- Daraxonrasib Phase 3: drug doubles one-year survival (5)
- Market scramble: Revolution Medicines' fundraising and buyout buzz (3)
- Other pancreatic research, methods and early-stage KRAS studies (5)
- All Other Stories
Clinicians celebrate landmark KRAS win; cautious optimism prevails
Daraxonrasib Phase 3: drug doubles one-year survival
Market scramble: Revolution Medicines' fundraising and buyout buzz
Other pancreatic research, methods and early-stage KRAS studies
All Other Stories
American Cancer Society Announces New Pediatric, Adolescent, and Young Adult Cancer Journal; Names Editor-in-Chief
cancer - The publication will provide a platform to share discoveries and advance knowledge across the field of pediatric and AYA oncology
AI Summary: The American Cancer Society launched a new open‑access journal dedicated to pediatric, adolescent and young adult oncology and named its inaugural editor‑in‑chief. The journal aims to centralize research, clinical guidance and policy discussions for younger patients, speeding dissemination of age‑specific evidence and, one hopes, improving outcomes for a frequently overlooked group.
- ACS launches open‑access journal centralizing pediatric and AYA oncology research (7)
- Adolescents and young adults: awareness, survivorship, transition and community (9)
- Global pediatric oncology gatherings spotlight collaboration, training and innovation (14)
- Other pediatric oncology news: research, partnerships, advocacy and care (24)
- All Other Stories
ACS launches open‑access journal centralizing pediatric and AYA oncology research
Adolescents and young adults: awareness, survivorship, transition and community
Global pediatric oncology gatherings spotlight collaboration, training and innovation
Other pediatric oncology news: research, partnerships, advocacy and care
All Other Stories
Scientists finally uncover why promising cancer drugs keep failing
sciencedaily - Cancer drugs known as BET inhibitors once looked like a breakthrough, but in real patients they’ve often fallen short. New research reveals a key reason why: two closely related proteins, BRD2 and BRD4, don’t actually do the same job. Instead, BRD2 acts l…
AI Summary: Scientists uncovered a cellular survival mechanism that helps tumors withstand DNA damage, offering a concrete explanation for why numerous promising anti‑cancer agents stumble in clinical trials. The discovery exposes a resistance pathway that blunts drug efficacy and suggests new targets to sensitize tumors and potentially revive stalled therapies — which, yes, might finally save some development budgets.
- BET inhibitor paradox — BRD2 preps, BRD4 triggers gene activation (3)
- OTHER — Diverse resistance mechanisms and maps of tumor adaptation (6)
- Replication-fork rescue — Tumors patch DNA breaks to survive therapy (3)
- RNA regulation vulnerabilities — RNA editing and noncoding RNAs expose targets (3)
- All Other Stories
BET inhibitor paradox — BRD2 preps, BRD4 triggers gene activation
OTHER — Diverse resistance mechanisms and maps of tumor adaptation
Replication-fork rescue — Tumors patch DNA breaks to survive therapy
RNA regulation vulnerabilities — RNA editing and noncoding RNAs expose targets
All Other Stories
Gilead Activates Its Pipeline: Option Exercises at Cartography Bio and Kymera Signal Accelerating Oncology Execution
oncodaily - In a pair of announcements that underscore Gilead Sciences’ intensifying commitment to oncology, two of its collaboration partners, Cartography Biosciences and Kymera Therapeutics, revealed today that Gilead has exercised exclusive […]
AI Summary: Gilead moved to accelerate its oncology strategy by exercising option agreements with smaller biotech partners, including Kymera and Cartography Bio. The moves signal targeted investment in protein degraders and other novel modalities, shoring up the company’s mid‑stage pipeline and hinting that big pharma still prefers buying options to inventing overnight.
Oricell Lands $110M to Take Cell Therapy to New Territory in Cancer
Frank Vinluan / medcitynews - There are no FDA-approved therapies for GPC3, a protein highly expressed by liver cancers. Oricell Therapeutics claims its cell therapy could be best in this class, but it faces competition from companies such as AstraZeneca and Eureka Therapeutics. The p…
AI Summary: Oricell, a China‑based CAR‑T developer, secured fresh financing to accelerate its cell‑therapy programs and support plans to go public. The fundraising will bankroll clinical expansion, manufacturing scale‑up, and regulatory preparations as the company pushes toward broader development and an IPO ambition, positioning it to compete in the crowded CAR‑T market.
FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
esmo - Evidence for efficacy is based on the findings from the ROSELLA study
AI Summary: The FDA granted marketing authorization for relacorilant in combination with nab‑paclitaxel to treat platinum‑resistant epithelial ovarian, fallopian tube and primary peritoneal cancers. Regulators cited clinical benefit in a difficult‑to‑treat population, providing an additional therapeutic option for patients with limited choices and marking an important regulatory milestone.
James P. Allison, PhD, FAACR, Honored With the 2026 AACR Award for Lifetime Achievement in Cancer Research
oncodaily - James P. Allison has been honored with the 2026 AACR Award for Lifetime Achievement in Cancer Research, a distinction recognizing his extraordinary scientific achievements and enduring impact on modern oncology. […]
AI Summary: James P. Allison received the 2026 AACR Award for Lifetime Achievement in Cancer Research for pioneering work in cancer immunotherapy. The award recognizes decades of transformative science that helped establish immune‑checkpoint blockade as a foundational cancer treatment, altering therapeutic strategies across multiple tumor types.
Antoni Ribas, MD, PhD, FAACR, Honored With the 2026 AACR-Margaret Foti Award
oncodaily - The American Association for Cancer Research (AACR) has named Antoni Ribas as the recipient of the 2026 AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research, recognizing a […]
AI Summary: Antoni Ribas was honored with the AACR‑Margaret Foti Award in recognition of leadership and major contributions to cancer research. The award spotlights Ribas’ influence on immunotherapy development and cancer science translation, celebrating a career that has shaped both scientific agendas and clinical practice.
Cancer Risk Is Significantly Higher for Adults Who Never Married, Large Study Finds
oncodaily - Analysis of 4 million cases finds higher cancer rates across most types, especially for preventable cancers. Adults who have never been married face a significantly higher risk of developing cancer […]
AI Summary: A large observational analysis found that adults who never married have a significantly higher cancer risk compared with married peers, after adjusting for common confounders. Researchers highlight social, behavioral and access‑to‑care factors as possible contributors, suggesting that relationship status may serve as a marker for targeted prevention and support interventions.
- Lifestyle, sleep and fertility linked to cancer risk (3)
- Never-married adults face significantly higher cancer risk (3)
- Place, education and loneliness drive cancer disparities (3)
Lifestyle, sleep and fertility linked to cancer risk
Never-married adults face significantly higher cancer risk
Place, education and loneliness drive cancer disparities
UCLA Researchers Develop Low-Cost Blood Test to Detect Multiple Cancers And Other Diseases From a Single Sample
oncodaily - The new method analyzes genome-wide methylation of DNA circulating in the bloodstream to detect liver, lung, ovarian and stomach cancers, as well as several non-cancer conditions. UCLA scientists have developed […]
AI Summary: Researchers at UCLA introduced a low-cost blood test capable of detecting multiple cancers and other diseases from a single sample, promising broader screening reach and earlier detection. If validated at scale, the technology could lower barriers to multi-cancer screening, reshape diagnostic pathways, and offer cheaper, simpler surveillance—assuming the usual caveats about follow-up testing and false positives.
- Frontline: ctDNA and cfDNA - monitoring, screening, and reliability questions (4)
- On location: early-detection debates, AI risk stratification and screening value (4)
- On the ground: UCLA’s inexpensive blood test expands multi-disease detection (4)
- All Other Stories
Frontline: ctDNA and cfDNA - monitoring, screening, and reliability questions
On location: early-detection debates, AI risk stratification and screening value
On the ground: UCLA’s inexpensive blood test expands multi-disease detection
All Other Stories
Gilead continues dealmaking streak with $3.15B Tubulis buy for ADCs
Kyle LaHucik / endpoints - In its third acquisition of 2026, Gilead is spending $3.15 billion upfront to snag a next-generation antibody-drug conjugate platform from German startup Tubulis. The California biopharma could pay out another $1.85 billion down the road ...
AI Summary: Gilead Sciences struck a multibillion-dollar acquisition to add Tubulis and bolster its oncology pipeline, buying into antibody-drug conjugate technology. The deal signals Gilead’s strategic pivot to expand beyond infectious disease into cancer therapeutics, accelerating access to novel modalities and reshaping competitive dynamics in biopharma.